Research Article Acute Oral Toxicological Profile of Croton membranaceus Mull. Arg. Aqueous Stem Extract, a Herbal Treatment for Benign Prostate Hyperplasia, in Male Sprague–Dawley Rats Daniel Kwame Afriyie ,1 Elvis Ofori Ameyaw ,2 Isaac Tabiri Henneh ,2 George Asare,3 Ebenezer Ofori-Atta ,4 Seth Kwabena Amponsah ,5 and Regina Appiah-Opong 4 1Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana 2Department of Pharmacotherapeutics and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of Cape Coast, Cape Coast, Ghana 3Department of Medical Laboratory Sciences, University of Ghana, Accra, Ghana 4Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana 5Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana Correspondence should be addressed to Daniel Kwame Afriyie; dspdan77@yahoo.com Received 27 September 2023; Revised 12 February 2024; Accepted 23 February 2024; Published 7 March 2024 Academic Editor: Lissinda H. Du Plessis Copyright © 2024 Daniel Kwame Afriyie et al.Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Croton membranaceus Mull. Arg. is a traditional medicinal plant frequently employed in Ghana for the treatment of benign prostatic hyperplasia and prostate cancer. Te objective of this study was to determine the acute oral toxicity of the aqueous stem extract of Croton membranaceus (CMASE) in male Sprague–Dawley (S-D) rats. Te acute toxicity of CMASE was evaluated using S-D rats randomly divided into four groups of fve animals each. Tree groups (low dose, median dose, and high dose) of rats received single oral doses of CMASE (1000, 2500, and 5000mg/kg body weight, respectively) using an oral gavage. Te control group was given distilled water. After 14 days of daily observations, hematological, biochemical, and histopathological analyses were conducted on the rats. From the results obtained, doses of CMASE up to 5000mg/kg did not cause death or induce any clinical indications of toxicity during the study period. Also, the mean body weight and the hematological indices assessed were not signifcantly afected by the various doses of CMASE compared to the control group. However, serum uric acid and creatinine levels decreased signifcantly (p< 0.001) 14 days after the extract administration. Serum liver function enzyme levels, including alkaline phosphatase (ALP), alanine aminotransferases (ALT), and aspartate aminotransferases (AST), and serum proteins (total proteins and albumin) exhibited signifcant (p< 0.001) non dose-dependent changes (increases and decreases) in treated groups compared to the controls. Other biochemical indices, however, did not difer signifcantly between the treated groups and the controls. Te gross pathological and histological analysis of the heart, liver, and kidney tissues did not reveal any signifcant changes in histoarchitecture. Te oral LD50 of CMASE in rats was greater than 5000mg/kg, indicating that the extract was relatively safe. It must, however, be used with care as a substitute for the roots. 1. Introduction Te global incidence of benign prostatic hyperplasia (BPH) has increased signifcantly from 51.1 million cases in 2000 to 94 million cases in 2019 [1]. Typically, the onset of BPH symptoms occurs in middle-aged men (35 years or older), and by age 50, an estimated 50% of men have been diagnosed with the condition; thereafter, the incidence of BPH cases increases linearly with age [2]. BPH prevalence in Africa and West Africa is believed to be very high despite the fact that there is paucity of data to support this claim. Among the few reports from the continent is one from South Africa which Hindawi Journal of Toxicology Volume 2024, Article ID 7526701, 12 pages https://doi.org/10.1155/2024/7526701 https://orcid.org/0000-0001-8859-3565 https://orcid.org/0000-0002-8317-9602 https://orcid.org/0000-0002-6830-0283 https://orcid.org/0000-0002-8201-2499 https://orcid.org/0000-0001-7411-0972 https://orcid.org/0000-0003-4219-7107 mailto:dspdan77@yahoo.com https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ indicates a prevalence of over 50% in adult males of over 60 years old [3]. Also, a study in a rural setting in Nigeria found 23.7% prevalence among male adults [4]. In a Gha- naian study, the prevalence of digital rectal examination- (DRE-) detected enlarged prostates in 950 men aged 50–74 was found to be 62.3% [5]. All these data suggest a high prevalence of BPH on the African continent. BPH is known to be caused by an imbalance in the proliferation of epithelial and stromal cells in the prostate, which occurs in aging men [6, 7]. Tamsulosin and alfuzosin (alpha-1 blockers), in conjunction with traditional 5α-re- ductase inhibitors (fnasteride and dutasteride), have been themainstay of pharmacotherapy for BPH over the years [8]. However, the use of these conventional drugs has been limited by their numerous side efects, which include diz- ziness, postural hypotension, headache, tachycardia, ab- normal ejaculation, and somnolence, among others [9]. Tis has resulted in increased patronage of medicinal plant al- ternatives, which are considered to be generally safer, easily assessable, and afordable [10]. One of these plant alterna- tives is Croton membranaceus Mull. Arg. (family, Euphorbiaceae). Croton membranaceus is a well-known traditional medicinal plant in Ghana and the West African subregion for its antibenign prostatic hyperplasia and antiprostate cancer properties from its root extracts [11, 12]. Te plant belongs to the genus Croton and is one of the 1300 species in the family Euphorbiaceae [13]. Earlier studies on the root bark of the plant revealed that it contained scopoletin and julocrotine [14], with the molecular structure of the former constituent resembling terazosin, a synthetic alpha-1 blocker used conventionally for the relaxation of smooth muscles around the urethra in BPH management [15]. Owing to the growing interest in the medicinal prop- erties of C. membranaceus, tremendous scientifc studies have been undertaken over the past decades on its root extracts, following the initial studies by Aboagye [12] that sought to establish whether it possessed 5-alpha reductase inhibitory activity. Te aqueous root extracts of C. membranaceus have been subjected to acute and sub- chronic toxicity tests, which have validated their safety as well as their anti-ischaemic and anti-antherogenic potentials [16, 17]. Tere have also been some toxicity studies on the leaves and stem extracts of the plant [17–19]. But it is im- portant to note that, aside from the study by Asare et al. [17]; who conducted a comprehensive toxicological assessment on the root of the plant that encompassed hematological, serum biochemical, and histopathological evaluations, all other previous acute toxicity studies on the stem or root extracts of C. membranaceus concentrated on the obser- vation of only clinical symptoms of toxicity. It is worth noting that not all hematological, serum biochemical, and histopathological abnormalities are clinically manifested [20]. Tis implies that although a test agent may not exhibit clinical signs of toxicity, there could be serious abnormalities in internal vital organs, thus leading to death in the long term. It is important to suggest that test agents that have been declared safe based on only clinical signs of toxicity should be subjected to a detailed toxicological assessment for optimum safety of consumers. Due to increased demand for the root extract for BPH management in Ghana and the West Africa subregion, there have been undocumented reports of the replacement of root parts with the stem or a mixture of the stem and roots for improved yield without recourse to toxicity evaluation of the stem extract. It is worth noting that the medicinal and/or toxicological efects of one part of a plant cannot be ex- trapolated to the other part of the plant since diferent plant parts are known to contain diferent secondary metabolites in diferent concentrations [21, 22]. It is very vital for the toxicity profle of medicinal plant extracts to be established before they are marketed as “safe” natural products [23].Te study, therefore, aimed at providing an in-depth acute toxicological evaluation of the aqueous stem extract of C. membranaceus for future preclinical studies. 2. Materials and Methods 2.1. Plant Collection and Extraction. Te collection of the plant and extraction procedure has been described pre- viously [24]. Whole plants of C. membranaceus were col- lected during the morning in the month of December, at Mampong-Akwapem (5°35′28″N, 0°14′59″W) in the East- ern region of Ghana. Taxonomists at the Center for Plant Medicine Research (CPMR) verifed its authenticity. A voucher specimen of the plant (UCCG-DCOP-007) was deposited at the University of Ghana’s herbarium. Te extract was prepared using the modifed validated procedure by Afriyie et al. [16]. Te stem of the plant were carefully cleaned and allowed to air dry for three weeks. Te dried stems were then pulverized into a powder using a milling machine, and the powdered material was sealed in zip-lock bags with labels and kept at room temperature (25°C). Ten, 1 kg of the powdered plant part was cold macerated for 24 hours with 4 L of distilled water and heated on a water bath at 100°C for 1 hour. After cooling, the extract was fltered through sterile gauze. Te second and third extracts were prepared by repeating this procedure with 3 L of distilled water and then cooling them. After gathering the extracts, they were freeze-dried. Before being used for the in vivo experiment, the percentage yield of the freeze-dried material was determined to be 1.78% using the following formula: Percentage yield � Weight of dried extract(g) Weight of dried powdered plant sample(g) × 100. (1) 2 Journal of Toxicology Te freeze-dried extract was then kept in air-tight amber-colored containers and immediately kept in a re- frigerator between 2 and 8°C. Te aqueous stem extract of C. membranaceus (CMASE) procedure was selected based on folkloric preparation protocols. 2.2. Experimental Animals. For this study, healthy male Sprague–Dawley (S-D) rats (6-7weeks old) weighing 110–130 g were used. Rats were purchased from the Animal Experimentation Unit of the Noguchi Memorial Institute for Medical Research. Te animals were acclimatized for fve days before the experiment, and they were kept at room temperature of 25±1°C and at a humidity of 50–60%. Tey were also maintained at 12 hour light/day cycle. Tey were fed with conventional laboratory rat diet (Agricare, Kumasi, Ghana) and were given free access to clean water. Te an- imals were given a 12 hour fast before treatment after which the laboratory conditions continued throughout the ex- periment. Te study strictly followed the guidelines outlined by the National Institute of Health’s “Guide for the Care and Use of Laboratory Animals.” Ethical clearance was obtained from the Institutional Animal Care and Use Committee at the Noguchi Memorial Institute for Medical Research’s Department of Animal Experimentation, University of Ghana with approval number (UG-IACUC 003/18-19). 2.3. Acute Toxicity Study. Te experimental procedure used in conducting the experiment has been described previously [24]. Te acute toxicity study was performed following the Organisation for Economic Co-operation and Development Guidelines for Testing Chemicals with little modifcations (OECD 420, 2001). A total of 20 healthy S-D male rats were randomly divided into four groups (n� 5/group). Briefy, instead of the recommended doses of 50, 100, 300, and 2000mg/kg, higher doses of 1000 to 5000mg/kg were used. Tis was due to the fact that earlier studies conducted on the root used doses as high as 3000mg/kg and no death was recorded at such a high dose [17]. Te distinct, permanent color markings on the head, tail, back, right foreleg, and left hind leg allowed researchers to identify the rats in each group. Te three groups of rats (low dose (LD), median dose (MD), and high dose (HD)) each received a single oral dose of 1000, 2500, and 5000mg/kg extract, respectively. Distilled water was administered orally to the control group. Te rats were observed for clinical toxidrome signs in the form of altered skin, fur, eyes, respiratory pattern, movement, and mucous membranes at 0, 1, 3, and 6 hours postextract ad- ministration, as well as every day up until the 14th day. Daily food and water consumption of rats was monitored. Fur- thermore, body weights of the rodents were documented on days zero, seven, and fourteen subsequent to the extract’s administration. On the ffteenth day, the rats were anes- thetized with pentobarbitone 50mg/kg i.p. Blood was col- lected via cardiac puncture into EDTA (ethylenediamine- tetraacetic acid)-2K tubes for hematological analysis, and portions were collected into gel-separator tubes for bio- chemical analyses. Afterwards, the rats were euthanized and vital organs/tissues such as the liver, heart, kidney, and prostate were harvested for histopathological analysis. Carcasses of the animals were buried in a designated area following local institutional ethical guidelines as well as the “Guidelines for the Euthanasia of Animals” published by the American Veterinary Medical Association [25]. 2.3.1. Hematological Analysis. Hematological parameters including total red blood cells (RBC), total white blood cells (WBC), hemoglobin levels (HGB), packed cell volume (PCV), hematocrit (HCT), platelet counts (PCT), mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), and mean corpuscular hemoglobin (MCHC) were analyzed according to Baker et al. [26]. 2.3.2. Biochemical Assessment. After being collected into gel separator tubes and letting them clot for 30minutes,blood samples were processed for serum by centrifuging (using HUMAX-K, Human-Germany) them for 5minutes at 3000 rpm. Before use, Sera were kept at −20°C. Using the Selectra Junior Autoanalyzer (Vital Scientifc Bv, Version 04, Netherlands), serum samples were examined for a variety of biochemical markers, including total protein, albumin, total bilirubin, alkaline phosphatase (ALP), alanine amino- transferase (ALT), aspartate aminotransferase (AST), total cholesterol, urea, lactate dehydrogenase (LDH), creatine kinase-R (CK-R), and lipids. 2.3.3. Histopathology. Te liver, heart, kidney, and prostate tissues were harvested for histopathological examinations. Te weights of the harvested organs were determined using a standard weighing balance after cleaning and washing with normal saline and drying with blotting paper. Te organs were subsequently processed for histopathological studies after being fxed with 10% bufered formalin. Hematoxylin and eosin (H&E) was used to stain the sectioned tissues (5 µm) of these organs that were embedded in parafn. Slides were examined using an Olympus CX23 light microscope (model CX23LEDRFSI, China). 2.4. Statistical Analysis. GraphPad® Prism Software Version 9.3.1 (San Diego, California, USA) for Windows® 10 was utilized in the analysis of data and plotting of graphs in this study. Results were presented as mean± the standard error of the mean (S.E.M.). To establish a signifcant diference analysed parameters between the treatment groups and control group, either a one-way ANOVA followed by Dunnet’s post hoc test or two-way ANOVA followed by Tukey’s post hoc multiple comparison analysis was used. P values less than 0.05 considered statistically signifcant. 3. Results 3.1. Animal Survival and Clinical Observations. Results ob- tained from the study, as presented in Figure 1, indicate that treatment of the rats with various doses of CMASE did not cause death in any of the treated animals. Also, none of the treated groups experienced any toxicity-related symptoms Journal of Toxicology 3 such as restlessness, grooming, tremors, convulsions, pu- pillary dilation, pinna refex, salivation, or lacrimation. In general, all groups experienced an increase in body weight at the end of the 14-day experiment. However, rats given the aqueous stem extract of C. membranaceus (1000, 2500, and 5000mg/kg) did not gain any body weight that was sig- nifcantly diferent from control rats (p > 0.05).Te low and median dose groups experienced the greatest weight gains, whereas the high dose group experienced the least weight gain. 3.2.HematologicalAnalysis. Table 1 presents comprehensive fndings on the efects of acute CMASE administration on hematological indices using S-D rats after 14 days. Results generally showed no signifcant diferences in hematological indices between the CMASE treated and control groups (p > 0.05). Comparing the treated rat groups to the control, there was typically no dose-dependent pattern of the efect of diferent doses of CMASE on the hematological parameters. HGB, RBC, WBC, HCT, MCV, and MCH values were generally slightly lower in the low and median groups than in the control group, whereas the high dose groups’ values were slightly higher than their respective controls. Te mean MCHC, LYM%, and LYM count (#) values were marginally higher in the treated groups than the values obtained in the control group. 3.3. Biochemical Analysis. Table 2 provides information on CMASE’s efects on S-D male rats’ biochemical parameters at the conclusion of the study. Regarding these indices: gamma-GT, total bilirubin, direct bilirubin, indirect bilirubin (I-BIL), total cholesterol (TC), total triglycerides, HDL, LDL, and urea values, no statistically signifcant (p> 0.05) diferences between serum levels among the treated groups and controls were found. Additionally, neither a general nor a dose-dependent pattern of CMASE’s efects was seen in these treated groups. All of the examined liver enzyme indices (ALT, AST, and ALP) showed signifcant (p< 0.001) diferences between the treated and control groups. No dose-dependent patterns of CMASE’s impact on these liver indices were observed. Also, signifcant (p< 0.001) diferences were found between the mean serum values obtained for total proteins, globulins, and albumin between the treated and control groups. Al- though some treated groups showed signifcantly lower levels of TP and ALB compared to controls, the values obtained for these indices in the treated groups did not exhibit any dose-dependent pattern. In general, the mean lipid indices for TG, TC, HDL, and LDL obtained in the low and median dose groups were lower than their corre- sponding control mean values, whereas the high dose values for these indices were marginally higher than their corre- sponding control group mean values.Temean serum levels of uric acid and creatinine were signifcantly lower in the treated groups when compared to the control group with regard to the kidney function indices (p< 0.001). 3.4. Efect of CMASE on Creatine Kinase and Lactate Dehydrogenase. Fourteen days following the single-dose administration of CMASE, serum levels of lactate de- hydrogenase and creatine kinase in the treatment groups were not signifcantly (p> 0.05) altered compared to the To ta l b od y w ei gh t ( g) Control CMASE 1000 mg/kg CMASE 2500 mg/kg CMASE 5000 mg/kg 100 120 140 160 180 140 7 Day Figure 1: Efect of extract of CMASE on the body weights of male S-D rats 14 days postoral administration of test agents. Data are presented as mean± SEM. n� 5. Tere were no signifcant diferences between treatment and control using two-way ANOVA. 4 Journal of Toxicology control group. However, a slight elevation of serum levels for these indices was seen with increasing doses of CMASE. Figure 2 displays the mean serum values for lactate de- hydrogenase and creatine kinase. 3.5. Histopathology and Relative Organ Weights 3.5.1. Organ Weights of Male S-D Rats. Te mean organ weights of the liver, heart, and kidney of the treated groups compared to the control group were not signifcantly dif- ferent when they were examined 14 days postacute dose administration of CMASE. Additionally, CMASE had no dose-dependent efects on the organ weights of any of the treated groups (Table 3). 3.5.2. Gross Pathological and Macroscopical Examination. Macroscopically, the kidneys of the CMASE-treated rats were not signifcantly diferent from the control group rats. Tey all had a reddish brown and bean-shaped appearance. Also, the liver of both control and treated group rats appeared normal with smooth, frm consistency and reddish brown in color. Similarly, macroscopical features of the heart had a conical-shaped reddish-brown appearance in control and treatment group rats. Gross anatomical features of the heart, liver, and kidneys of rats in the CMASE-treated groups were not markedly diferent from those in the control group. No serious ab- normalities or damages were observed in any of the organs examined. Sections of these organs were further examined Table 1: Hematological parameters of S-D rats after 14 days of administration of CMASE. Hematological parameters Rat groups Control Low dose 1000mg/kg Median dose 2500mg/kg High dose 5000mg/kg P value WBC× 103 (μl) 13.42± 1.60 12.53± 2.21 11.95± 1.46 14.39± 1.57 0.770 RBC× 106 (μl) 8.35± 0.15 7.99± 0.29 7.86± 0.13 8.57± 0.40 0.285 HGB (g/dL) 14.73± 0.25 14.14± 0.53 14.00± 0.31 15.28± 0.25 0.077 HCT (%) 47.73± 0.73 45.44± 2.07 44.50± 0.72 48.58± 1.68 0.190 MCV (fL) 57.18± 1.33 56.92± 1.69 56.64± 0.8 56.78± 1.05 0.992 MCH (pg) 17.63± 0.35 17.72± 0.49 17.58± 0.32 17.88± 0.42 0.954 MCHC (g/dl) 30.85± 0.22 31.18± 0.26 32.48± 1.2 31.45± 0.15 0.323 PLT×103 (μl) 767± 96.7 576.8± 26.85 533.8± 50.97 631± 29.37 0.059 LYM (%) 68.65± 2.23 74.52± 3.25 68.06± 2.26 71.33± 2.39 0.302 LYM (#×103/μl) 9.25± 1.24 9.31± 1.75 8.40± 0.93 10.38± 1.46 0.792 Data are presented asmean± SEM. n� 5. P values were obtained from one-way ANOVA (treatment groups compared to control for each parameter). Since, p values were greater than 0.05, thus there were no signifcant diferences between treatment and control groups. WBC�white blood cells; RBC� red blood cells; HGB� hemoglobin levels; HCT� hematocrit; MCV�mean cell volume; MCH�mean corpuscular hemoglobin; MCHC�mean cell hemoglobin concentration; PLT�platelet counts; LYM� lymphocytes. Table 2: Biochemical indices of S-D rats treated with acute doses of CMASE after 14 days. Biochemical parameters Control Low dose 1000mg/kg Median dose 2500mg/kg High dose 5000mg/kg T-BIL (μmol/l) 0.60± 0.35 0.38± 0.16 0.44± 0.16 0.35± 0.06 D-BIL (μmol/l) 1.28± 0.24 1.23± 0.16 1.00± 0.02 1.51± 0.16 IBIL (μmol/l) 0.85± 0.25 1.10± 0.25 1.14± 0.09 0.98± 0.19 ALT (U/L) 78.15± 0.92 60.75± 0.57∗∗ 87.83± 0.13∗∗L 73.75± 0.86L,M AST (U/L) 267.70± 0.52 245.30± 0.50∗∗ 395.38± 0.04L 301.90± 0.59L,M ALP (U/L) 390.78± 0.30 435.55± 0.32∗∗ 449.08± 0.95L 304.75± 0.39L,M Gamma-GT 1.38± 0.27 1.60± 0.52 1.90± 0.58 1.75± 0.19 TP (g/l) 66.73± 0.71 58.55± 0.25∗∗ 63.23± 0.64∗∗L 66.68± 0.20L,M ALB (g/dL) 35.05± 0.78 29.55± 0.98∗∗ 35.40± 0.57L 34.38± 0.59L Glo (g/dL) 31.68± 0.89 28.13± 0.40∗ 28.85± 0.93 33.78± 0.97L,M AST/ALT 3.45± 0.17 4.53± 0.46 5.15± 0.67 3.40± 0.17 TC (mmol/L) 2.45± 0.19 2.09± 0.12 1.98± 0.17 2.51± 0.16 TG (mmol/L) 1.46± 0.15 1.27± 0.12 1.44± 0.14 1.80± 0.29 LDL (mmol/L) 0.59± 0.09 0.46± 0.02 0.45± 0.03 0.58± 0.06 HDL (mmol/L) 0.99± 0.04 0.89± 0.04 0.91± 0.08 1.09± 0.04 CREA (mmol/L) 64.30± 0.80 52.39± 0.95∗∗ 56.55± 0.53∗∗L 57.87± 0.80∗∗L UREA (mmol/L) 6.15± 0.55 6.73± 0.32 6.65± 0.16 5.34± 0.43 URIC ACID (mmol/L) 211.60± 0.19 148.33± 0.65 175.35± 0.02∗∗ 156.23± 0.74∗∗LM Data are presented as mean± SEM. n� 5. Te symbols ∗ and ∗∗ represent p< 0.05 and p< 0.01, respectively, whereas, Lp< 0.01 compared to the low dose group. Mp< 0.01 compared to the median dose group (two-way ANOVA followed by Tukey’s post hoc test). HDL� high-density lipoprotein; LDL� low-density lipoprotein; VLDL� very low-density lipoprotein; SEM� standard error of mean; T-BIL� total bilirubin; D-BIL� direct bilirubin; I-BIL; TP� total protein; TC� total cholesterol; ALB� albumin; Glo� globulin; TG� triglycerides; CREA� creatinine; gamma GT�gamma-glutaryl transferase. Journal of Toxicology 5 histologically, most organs showed normal morphological and staining features, with few mild pathological lesions. Where pathological lesions were present, they were mild and potentially reversible. Heart tissue sections from both the treated and control groups were normal without any infarcts or leucocyte infltrations (Figure 3). Also, sections from the kidneys of the treated and control groups displayed normal renal tissue, including dilated tubules, a few congested renal tissues, and no tubular or glomerular necrosis (Figure 4). Moreover, sections from the liver of both treated and control groups showed only a few spots of dilated central veins, but there were no hepatocellular necrosis in the tissues (Fig- ure 5). In summary, the liver, kidney, and heart of both the treated and control groups showed similar morphological features histologically, with very little or no evidence of CMASE-induced damage. 4. Discussion Ethnomedicinal plants have been used in folk medicine to treat various ailments. Teir natural origin has fueled the erroneous assumption that they are very safe and devoid of possible serious adverse efects [10, 27]. To guarantee their safety for human consumption and marketing, medicinal plant extracts and other potential drug molecules must undergo toxicological and pharmacological evaluations as required by regulatory agencies. Te initial test conducted to gather information on the hazardous properties of a substance is the acute oral toxicity test.Tis test enables the substance to be categorized and classifed based on the Globally Harmonized System (GHS) for chemicals causing acute toxicity [28]. One of such medicinal plants that have been used extensively for the treatment of benign prostate hyperplasia is the Croton membranaceus despite its limited toxicological assessment, especially for the stem. Oral administration of single high doses of Croton membranaceus aqueous stem extract, CMASE (1000, 2500, and 5000mg/kg) in this study to male S-D rats was found to be almost nontoxic to the animals. In fact, no signs of be- havioral or clinical toxicity or mortality were seen during the study’s time frame.Te present study therefore suggests that the aqueous stem extract falls under the Globally Harmo- nized Classifcation System (GHS) unclassifed category and that the LD50 of the extract is greater than 5000mg/kg [28]. Results from this section of the study were comparable to those from related studies on acute toxicity that used C. membranaceus root extracts [17–19]. In the aforemen- tioned studies, no serious signs of toxicity or death were recorded for the extracts at doses as high as 3000mg/kg. Tus, the stem, root, and leaves of Croton membranaceus could be said to nontoxic even at high doses. Upon exposure to toxic substances, abnormalities in body weight and internal organs are among the most im- portant sensitive indicators of toxicity that are mostly assessed [29, 30]. Studies have revealed that abnormal re- ductions in body weights of experimental animals could be 1000 800 600 400 200 0 Cr ea tin e K in as e ( IU /L ) Ctrl 1000 2500 5000 CMASE (mg/kg) (a) 15000 10000 5000 0 La ct as e D eh yd ro ge na se (I U /L ) Ctrl 1000 2500 5000 CMASE (mg/kg) (b) Figure 2: Efect of single-dose administration of CMASE (1000, 2500, and 5000mg/kg) on serum creatine kinase and lactate dehydrogenase values in S-D rats on the 14th day. Data are presented as mean± SEM (n� 5). Tere were no signifcant diferences between treatment and control using one-way ANOVA (p> 0.05). Table 3: Efect of single-dose administration of CMASE (1000, 2500, and 5000mg/kg) on organ weights of male S-D rats on the 14th day. Organ Control Low dose Median dose High dose P values Kidney (g) 1.20± 0.08 1.24± 0.06 1.04± 0.08 1.16± 0.07 0.97 Liver (g) 6.73± 0.19 6.87± 0.40 6.67± 0.21 7.00± 0.52 0.91 Heart (g) 0.62± 0.02 0.64± 0.04 0.56± 0.03 0.60± 0.05 0.52 Data are presented as mean± SEM. n� 5. Tere were no signifcant diferences between treatment groups and control group using one-way ANOVA (p> 0.05). 6 Journal of Toxicology suggestive of probable side efects or adverse reactions to test substances [31, 32], and reductions of initial weights beyond 10% are indicative of severe toxicity [33]. In this study, there were no appreciable diferences in the body weights of rats in the treated and control groups. Importantly, all groups of rats gradually grew in weight, and this could be attributed to the fact that the animals had regular dietary and hydration habits throughout the 14-day study period. Te extract’s potential for safety was indicated by the observations made regarding how acute doses of CMASE did not signifcantly Control group Low dose group Median dose group High dose group Figure 3: Photomicrograph of cross-section of the cardiac muscle in S-D male rats of the control, low, median, and high dose groups showing normal features of myocardium (H&E stain, ×40). Control Low dose group Median dose group High dose group Figure 4: Photomicrograph of S-D rat kidney showing the normal architecture of the glomeruli and tubules of the control low, median, and high dose group animals (H&E stain, ×40). Journal of Toxicology 7 afect body weights as well as food and water intake com- pared to the control group.Te extract is therefore not likely to exert any deleterious efects on the metabolic growth or health of consumers. Te results also suggest that there were no signifcant diferences in the mean organ weights of the liver, heart, and kidney between the treated groups and the control group when examined 14 days after the acute dose administration of CMASE. Signifcant changes in vital organ weights of treatment groups compared to the control group gives an indication of toxicity of test agents [34]. In this study, the absence of signifcant alterations in organ weights suggests that CMASE administration at the tested doses did not induce any overt adverse efects on these organs. However, according to OECD [28], further investigations involving hematological, biochemical, and histopathological assess- ments need to be conducted to ascertain the toxicity profle of the extract. Analysis of hematological indices such as HGB, WBC, RBC, and HCT aids scientists and clinicians in diagnosing the presence of anemia, while other related indices such as reticulocyte count, MCV, MCH, and MCHC are used to distinguish the type of anemia [24, 35]. Toxicological risk of blood parameters is vital because the bone marrow, being part of the hematopoietic system, is a target tissue for toxic compounds [29]. Consequently, it ofers sensitive predictive values for toxicity in humans using assays that involve ro- dents and other animals [36]; Adeneye et al., 2006; Olson et al., 2000. In this study, the hematological parameters (RBC, WBC, PLT, HGB, HCT, MCV, MCH, and MCHC) were compared between the control and CMASE-treated groups, and it was found that CMASE was not toxic to the hemopoietic system because there were no signifcant dif- ferences in these indices between the control and treated groups. Tese results agree with an earlier study by Asare et al. [17], who studied the aqueous root extract of the plant. It was observed that the administration of the extract does not adversely afect the hematopoietic system of rats. An- other closely related study on the stem extract of the plant only reported on clinical signs of toxicity without recourse to alterations in biochemical parameters [19], and that underscored the need for the present study. Another im- portant observation was that most of the hematological parameters were lower in the median dose compared to the low dose and the high dose groups, though insignifcant. Tis could be explained by the fact that hematological re- sponses can vary among individual animals, even when exposed to the same dose. Tis variability may lead to unexpected results where the median dose, which represents the middle value in a set of doses, happens to elicit lower responses compared to the lowest dose and the highest dose in some individuals [37]. According to Gowda et al. [38], signifcant increases in blood levels of creatinine, uric acid, and urea are signs of either abnormal kidney function or other diseases like glomerulonephritis, shock, congestive heart failure, poly- cystic kidney disease, acute tubular necrosis, and de- hydration. However, there were signifcant diferences in the levels of these biochemical parameters in the CMASE- treated groups compared to the control group in terms of creatinine and uric acid levels. Decreased serum creatinine levels mostly occur in subjects with muscular dystrophy paralysis, anemia, leukemia, and hyperthyroidism [39]. Te comparison with the study by Asare et al. [17] who assessed the root extract of the plant provides valuable context for interpreting the fndings of the present study. While the earlier study observed no signifcant changes in renal function parameters, such as urea and creatinine, with doses of 1500 and 3000mg/kg of the root extract of the plant, the present study found a signifcant reduction in creatinine Control group Low dose group Median dose group High dose group Figure 5: Photomicrograph of cross-section of the hepatic tissue in S-D rats showing normal features of hepatocytes in the control, low, median, and high dose groups animals (H&E stain, ×40). 8 Journal of Toxicology levels at doses ranging from 1000 to 5000mg/kg of the stem extract. Tis discrepancy in fndings suggests that diferent parts of the plant or diferent extraction methods may yield varying efects on renal function parameters. In addition, it underscores the importance of considering the specifc dosage and formulation used when assessing the safety profle of medicinal products derived from natural sources. Te signifcant reduction in creatinine levels observed in the present study at higher doses of the stem extract raises concerns regarding its potential impact on kidney function, particularly in individuals with pre-existing kidney im- pairment. Terefore, caution is warranted when using medicinal products containing these extracts, especially for individuals with renal dysfunction. Te liver is a major target and organ for drug bio- metabolism, so evaluation of liver indices is used as an indicator of the potential toxicity of test substances [40, 41]. Studies have demonstrated that hepatotoxic drugs or ex- tracts may cause liver damage that results in increased ALT, AST, and total protein levels [29, 42]. ALT is found in the liver and is therefore a much more sensitive marker for liver toxicity, as opposed to AST, which can also be found in the myocardium, skeletal muscles, brain, and kidney. Te study’s fndings demonstrated that acute oral administration of CMASE at doses between 1000 and 5000mg/kg caused a signifcant alteration in the serum levels of ALT, AST, and total proteins in the treated groups.Tis may suggest that the liver is a potential target organ for toxicity. However, on account of the fact that the histology did not show any abnormalities, hepatotoxicity is unlikely It is important to state that the results obtained difered from that obtained by Asare et al. [17], who found that the root extract of the plant did not cause signifcant alterations in AST or ALT levels in the serum of rats used. Te observation that median doses resulted in higher levels of AST, ALT, and ALP compared to both the high and low doses, despite all doses being signifcantly higher than the normal control, suggests a complex relationship between dose and the biochemical response. One possible explana- tion for this phenomenon is the biphasic or nonlinear nature of the dose-response curve for these parameters. In other words, the biochemical response may not increase linearly with increasing doses but rather reach a peak or plateau before declining or stabilizing at higher doses. Tis could be due to various factors, including saturation of metabolic pathways, receptor binding, or toxicological efects [37]. In addition, it is important to consider the mechanisms un- derlying the regulation of these enzymes in the body. AST, ALT, and ALP are produced primarily in the liver and are released into the bloodstream when liver cells are damaged or stressed. At lower doses, the body may be able to com- pensate for the increased enzyme production and maintain homeostasis to some extent. However, at higher doses, the cellular damage or stress may exceed the body’s compen- satory mechanisms, leading to a disproportionate increase in enzyme levels, thus accounting for the disparities between responses from the median and highest doses. Aronson and Ferner [37] also argued that in such circumstances, the observed efect may not be real, as it could have arisen due to random chance or methodological issues like bias or con- founding factors. Additionally, individuals vary greatly in their susceptibility to experiencing adverse reactions to test agents. Further investigations are therefore warranted to confrm the observation which also occurred in other bio- chemical parameters such as urea, uric acid, and albumin. Moreover, the liver is a major site of protein synthesis, and reductions in serum levels of total protein, albumin, and globulin could be suggestive of impaired hepatocellular function or hepatocyte damage [43]. Te study revealed a signifcant diference (p < 0.001) in serum levels of ALB and TP only between the low dose and control groups. Te results obtained deviated from an earlier which reported that total proteins, albumin, and globulin were not afected by low or high dose of root extract of Croton membranaceus administration [17]. Interestingly, it could be observed from the study that histological examination of the liver did not reveal any alteration of the histoarchitecture or damage. Triglycerides, total cholesterol, LDL, and VLDL are the most common lipids, and levels that are higher than the normal range suggest a higher risk of atherosclerosis, heart disease, stroke, and other cardiovascular diseases [44]. Al- though the 1000 and 2500mg/kg doses of CMASE appeared to have marginally reduced lipid parameters, the extract generally did not alter these parameters signifcantly, which indicates that its acute oral doses do not interfere with lipid metabolism adversely or induce cardiovascular diseases. Elevated serum enzyme levels of LDH and CK are biomarkers of heart or muscle damage [45]. Terefore, the levels of CK or CK-MB and LDH in toxicity studies have been used clinically to evaluate the degree of damage to the heart, skeletal muscles, and brain [46–48]. Te results of the current study suggest that acute oral doses of CMASE (C. membranaceus aqueous stem extract) did not cause any observable changes in the levels of creatine kinase (CK) and lactate dehydrogenase (LDH) in the serum. Tese markers are commonly used to assess potential toxicity to the brain, heart, or skeletal muscles. Te lack of signifcant changes in CK and LDH levels implies that CMASE may not exert toxic efects on these organs and tissues when administered orally. Comparing these fndings with a previous study conducted by Asare et al. [17], which investigated the efects of the root extract of the same plant, some diferences were noted. Specifcally, Asare et al. found that LDH levels were un- afected by the root extract, similar to the current study. However, they observed that CK and CK-MB levels were signifcantly lower in the groups treated with the root extract compared to the control group. Te juxtaposition of these studies suggests that diferent parts of the plant (stem extract vs. root extract) may have varying efects on cardiac markers such as CK and CK-MB. While the stem extract in the current study did not signifcantly alter CK and LDH levels, the root extract in the previous study led to lower CK and CK-MB levels.Tis highlights the importance of considering the specifc plant part and its extraction method when assessing potential physiological efects. In this study, no gross lesions were found in the tissues of the heart, liver, or kidney compared to the control group organs in the gross Journal of Toxicology 9 pathological and histopathology examinations. No signif- cant pathological lesions were found in the kidneys or livers of the treated groups despite some signifcant changes in some renal and liver function serum parameters.Tis could be due to the fact that many nephrotoxic plants, animal poisons, medications, chemicals, and illicit drugs can in- duce some level of acute kidney injury by varying the pathophysiological pathways and/or biochemical param- eters without necessarily causing acute structural changes in the kidney [49]. It is, therefore, important to note that the correlation between biochemical parameters and his- tological fndings is complex, and various factors can in- fuence the observed patterns. In clinical practice, a comprehensive assessment of kidney health often in- volves the integration of both biochemical and histological information, along with clinical context, to provide a more accurate understanding of renal function and potential pathology. Te same applies to other organs studied in which biochemical alterations did not manifest in struc- tural changes of the organs. Results from this study suggest that CMASE could be regarded as relatively safe following acute exposure and that the LD50 value may exceed 5000mg/kg. Tis study agrees with an earlier study by Appiah [19], who conducted pre- vious acute oral studies in S-D rats using doses of C. membranaceus aqueous stem extract up to 5000mg/kg in rats but reported only on clinical observations. Asare et al. [17], who also reported on the acute toxicity of the aqueous root extract of the plant, reported an LD50 that was greater than 3000mg/kg.Tis study also agrees with an earlier study by Sarkodie et al. [18] who reported that the LD50 of aqueous leaf extract of C. membranaceus was greater than 5000mg/ kg. It is worth mentioning that Sarkodie and his colleagues’ [18] study only looked out for clinical signs of toxicity and death without recourse to hematological, biochemical or histopathological investigations. Te current study, how- ever, reports on a comprehensive acute toxicity profle of stem extract encompassing clinical signs of toxicity, he- matological, serum biochemical, and histopathological toxicity profling.Tis, to our knowledge, is the frst in-depth acute toxicity study on the aqueous stem extract of C. membranaceus in rats. It is still recommended that ad- ditional studies involving repeated drug administration (subacute, subchronic, or chronic toxicity) should be conducted. 5. Conclusion Te results suggest that oral administration of the aqueous stem extract of C. membranaceus at doses up to 5000mg/kg did not result in mortality in the experimental animals, indicating a relatively low acute toxicity profle. Addition- ally, various parameters including behavioral observations, total body and organ weights, hematological parameters, and organ histology did not show signifcant diferences compared to the control group, further supporting the overall safety profle of the extract. However, caution is advised due to alterations observed in certain serum biochemical parameters. While the extract did not cause mortality or signifcant adverse efects on most physiological parameters measured, changes in serum bio- chemical parameters indicate potential physiological alter- ations that warrant attention. Tese alterations may suggest underlying efects on metabolic processes or organ function that could have implications for long-term health. Terefore, while the extract appears to be relatively nontoxic based on acute toxicity testing and general phys- iological parameters, the observed changes in serum bio- chemical parameters indicate the need for careful consideration when using the extract. Patrons and health- care providers should be aware of these potential efects and monitor for any signs of adverse reactions or physiological changes when using the extract, particularly at higher doses or with prolonged use. Further research, including subchronic and chronic toxicity studies, as well as clinical trials in human subjects, may provide additional insights into the safety profle and potential health efects of the aqueous stem extract of C. membranaceus. Additionally, investigating the underlying mechanisms of action responsible for the observed alter- ations in serum biochemical parameters could help elucidate the physiological efects of the extract and inform safer usage guidelines. Abbreviations CMASE: Aqueous stem extract of Croton membranaceus S-D: Sprague–Dawley ALP: Alkaline phosphatase AST: Aspartate aminotransferases BPH: Benign prostate hyperplasia OECD: Organisation for Economic Co-operation and Development EDTA: Ethylenediamine-tetraacetic acid RBC: Red blood cells WBC: White blood cells HGB: Hemoglobin levels PCV: Packed cell volume HCT: Hematocrit PCT: Platelet counts MCHC: Mean cell hemoglobin concentration MCV: Mean cell volume MCHC: Mean corpuscular hemoglobin LD: Low dose MD: Median dose HD: High dose LDH: Lactate dehydrogenase CK-R: Creatine kinase-R H&E: Hematoxylin and eosin ANOVA: One-way analysis of variance IBIL: Indirect bilirubin TC: Total cholesterol LYM: Lymphocyte GHS: Globally harmonized system HDL: High-density lipoprotein LDL: Low-density lipoprotein VLDL: Very low-density lipoprotein SEM: Standard error of mean 10 Journal of Toxicology D-Bil: Direct bilirubin TP: Total protein TC: Total cholesterol ALB: Albumin Glo: Globulin TG: Triglycerides CREA: Creatinine DRE: Digital rectal examination (DRE). Data Availability All data generated or analyzed during this study are included in this published article. Disclosure Tis research paper forms part of an earlier published PhD thesis by the frst author [24]. Conflicts of Interest Te authors declare that they have no conficts of interest. Authors’ Contributions DKA was involved in conceptualization, data curation, formal analysis, investigation, methodology, and wrote the original draft. EOA, GA, and RA-O were involved in conceptualization, methodology, supervision, validation, and wrote, reviewed, and edited the article. ITH and SKA contributed to data curation, formal analysis, investigation, and wrote and reviewed the article. All authors read and approved the fnal manuscript. References [1] M. A. Dirac, “Te global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. GBD 2019 Benign Prostatic Hyper- plasia Collaborators,” Lancet, vol. 3, pp. e754–e776, 2022. [2] K. L. Stewart and E. D. Lephart, “Overview of BPH: symptom relief with dietary polyphenols, vitamins and phytochemicals by nutraceutical supplements with implications to the pros- tate microbiome,” International Journal of Molecular Sciences, vol. 24, no. 6, p. 5486, 2023. [3] E. D. Yeboah, “Prevalence of benign prostatic hyperplasia and prostate cancer in Africans and Africans in the diaspora,” Journal of the West African college of surgeons, vol. 6, no. 4, pp. 1–30, 2016. [4] R. W. Ojewola, E. S. Oridota, O. S. Balogun et al., “Prevalence of clinical benign prostatic hyperplasia amongst community- dwelling men in a South-Western Nigerian rural setting: a cross-sectional study,” African Journal of Urology, vol. 23, no. 2, pp. 109–115, 2017. [5] A. P. Chokkalingam, E. D. Yeboah, A. Demarzo et al., “Prevalence of BPH and lower urinary tract symptoms in West Africans,” Prostate Cancer and Prostatic Diseases, vol. 15, no. 2, pp. 170–176, 2012. [6] R. Aleksandra, R. Iwona, M. Tomasz et al., “Metabolic syn- drome and benign prostatic hyperplasia: association or co- incidence?” Diabetology & Metabolic Syndrome, vol. 7, no. 94, pp. 1–7, 2015. [7] S. Tanguay, M. Awde, G. Brock et al., “Diagnosis and man- agement of benign prostatic hyperplasia in primary care,” Canadian Urological Association Journal, vol. 3, no. 3-S2, pp. 92–100, 2013. [8] T. J. Wilt, R. Mac Donald, and I. Rutks, “Tamsulosin for benign prostatic hyperplasia,” Cochrane Database of Sys- tematic Reviews, vol. 1, p. 2081, 2003. [9] G. Steineck, K. Bergmark, L. Henningsohn, M. al-Abany, P. W. Dickman, and A. R. Helgason, “Symptom documen- tation in cancer survivors as a basis for therapy modifca- tions,” Acta Oncologica, vol. 41, no. 3, pp. 244–252, 2002. [10] F. Adusei-Mensah, A. Haaranen, J. Kauhanen et al., “Post- market safety and efcacy surveillance of herbal medicinal products from users’ perspective: a qualitative semi- structured interview study in Kumasi, Ghana,” In- ternational Journal of Pharmaceutics & Pharmacology, vol. 3, p. 136, 2019. [11] M. I. Bayor, J. S. K. Ayim, R. M. Philips, S. D. Schynder, and C.W.Wright, “Te evaluation of selected Ghanaianmedicinal plants for cytotoxic activities,” Journal of Science and Tech- nology, vol. 27, no. 3, pp. 16–22, 2007. [12] F. A. Aboagye, “Te efect of Croton membranaceus on dihydrotestosterone levels in blood and its synthesis by prostatic 5 alpha-reductase in the rat,” Unpublished master of philosophy thesis, Department of Biochemistry, University of Ghana, Accra, Ghana, 1997. [13] W. H. Xu, W. Y. Liu, and Q. Liang, “Chemical constituents from Croton Species and their biological activities,” Mole- cules, vol. 23, no. 9, p. 2333, 2018. [14] F. A. Aboagye, G. H. Sam, G. Massiot, and C. Lavaud, “Julocrotine, a glutarimide alkaloid from Croton mem- branaceus,” Fitoterapia, vol. 71, no. 4, pp. 461-462, 2000. [15] M. Lambert, D. Stærk, S. H. Hansen, and J. W. Jaroszewski, “HPLC-SPE NMR hyphenation in natural products research: optimization of analysis of Croton membranaceus extract,” Magnetic Resonance in Chemistry, vol. 43, no. 9, pp. 771–775, 2005. [16] D. K. Afriyie, G. A. Asare, K. Bugyei et al., “Anti-atherogenic and anti-ischemic potentials of Croton membranaceus ob- served during sub-chronic toxicity studies,” Pharmacognosy Research, vol. 5, no. 1, pp. 10–16, 2013. [17] G. A. Asare, A. Sittie, K. Bugyei et al., “Acute toxicity studies of Croton membranaceus root extract,” Journal of Ethno- pharmacology, vol. 134, no. 3, pp. 938–943, 2011. [18] J. A. Sarkodie, A. A. Appiah, D. A. Edoh et al., “Anti- hyperglycaemic and antioxidant efects of Croton mem- branaceus Mull. Arg (Euphorbiaceae),” International Journal of Pharmaceutical Sciences and Research, vol. 5, no. 1, pp. 110–115, 2014. [19] A. A. Appiah, “Phytochemical and biological analysis of Croton membranaceus,” Unpublished doctoral thesis, Chemistry Department, University of Ghana, Accra, Ghana, 2011. [20] J. Tachil, S. Owusu-Ofori, and I. Bates, “Haematological diseases in the tropics,”Manson’s Tropical Infectious Diseases, vol. 894, pp. 894–932.e7, 2014. Journal of Toxicology 11 [21] P. Tiwari, B. Kumar, M. Kaur, G. Kaur, and H. Kaur, “Phytochemical screening and extraction: a review,” Inter- nationale Pharmaceutica Sciencia, vol. 1, no. 1, pp. 98–106, 2011. [22] I. T. Henneh, P. E. Owusu Agyei, E. Obese et al., “Leaf and root bark extracts of Ziziphus abyssinica Hochst ex. A. Rich (Rhamnaceae) ameliorate hepatic, renal and splenic injuries induced by phenylhydrazine in rats,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 32, no. 1, Article ID 20200111, 2021. [23] D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs from 1981 to 2014,” Journal of Natural Products, vol. 79, no. 3, pp. 629–661, 2016. [24] D. K. Afriyie, Pharmacological and toxicological evaluation of stem extracts of Croton membranaceus in benign prostatic hyperplasia and prostate cancer, Ph.D. thesis, Department of Biomedical Sciences, University of Cape Coast, Cape Coast, Ghana, 2020. [25] American Veterinary Medical Association (Avma), AVMA Guidelines for the Euthanasia of Animals, American Veteri- nary Medical Association, Schaumberg, IL, USA, 2020. [26] F. J. Baker, R. E. Silverton, and D. Kilshaw, Introduction to Medical Laboratory Technology, Butter 2007Worth, London, UK, 6th edition, 1985. [27] A. Arya, M. A. Abdullah, B. S. Haerian, and M. A. Mohd, “Screening for hypoglycemic activity on the leaf extracts of nine medicinal plants: in vivo evaluation,” E-Journal of Chemistry, vol. 9, no. 3, pp. 1196–1205, 2012. [28] Oecd, OECD Guideline for Testing of Chemicals: Acute Oral Toxicity – Fixed Dose Procedure, OECD Test Guide Line 420, OECD, Paris, France, 2001. [29] I. T. Henneh, W. Ahlidja, J. Alake et al., “Acute toxicity profle and gastroprotective potential of ethanolic leaf extract of Manihot esculenta Crantz,” Scientifc African, vol. 17, Article ID 1284, 2022. [30] S. L. Jothy, Z. Zakaria, Y. Chen, Y. L. Lau, L. Y. Latha, and S. Sasidharan, “Acute oral toxicity of methanolic seed extract of Cassia fstula in mice,” Molecules, vol. 16, no. 6, pp. 5268–5282, 2011. [31] F. Adusei-Mensah, C. Tikkanen-Kaukanen, J. Kauhanen et al., “Sub-chronic toxicity evaluation of top-three commercial herbal anti-malarial preparations in the Kumasi metropolis, Ghana,” Bioscience Reports, vol. 40, no. 6, Article ID 20192536, 2020. [32] M. Raza, A. S. Oa, E. H. Tm, and A. M. Aa, “Efect of pro- longed vigabatrin treatment on haematological and bio- chemical parameters in plasma, liver and kidney of Swiss albino mice,” Scientia Pharmaceutica, vol. 70, no. 2, pp. 135–145, 2002. [33] Y. Kulkarni and A. Veeranjaneyulu, “Toxicological studies on aqueous extract of Gmelina arborea in rodents,” Pharma- ceutical Biology, vol. 48, no. 12, pp. 1413–1420, 2010. [34] G. Owusu, M. Antwi-Adjei, and I. T. Henneh, “Pentobarbitone-induced sleeping time and sub-acute toxicity studies of Trichilia monadelpha aqueous extract,” In- ternational Journal of Basic & Clinical Pharmacology, vol. 5, no. 6, pp. 2352–2356, 2016. [35] R. Hillman and K. Ault, Haematology in Clinical Practice: A Guide to Diagnosis and Management, McGraw-Hill, New York, NY, USA, 2001. [36] M. Kifayatullah, M. S. Mustafa, P. Sengupta, M. M. R. Sarker, A. Das, and S. K. Das, “Evaluation of the acute and sub-acute toxicity of the ethanolic extract of Pericampylus glaucus (Lam.) Merr. in BALB/c mice,” Journal of Acute Disease, vol. 4, no. 4, pp. 309–315, 2015. [37] J. K. Aronson and R. E. Ferner, “Te Law of Mass Action and the pharmacological concentration–efect curve: resolving the paradox of apparently non-dose-related adverse drug re- actions,” British Journal of Clinical Pharmacology, vol. 81, no. 1, pp. 56–61, 2016. [38] S. Gowda, P. B. Desai, S. S. Kulkarni, V. V. Hull, A. A. Math, and S. N. Vernekar, “Markers of renal function tests,” North American Journal of Medical Sciences, vol. 2, no. 4, pp. 170– 173, 2010. [39] H. Shahbaz and M. Gupta, “Creatinine clearance,” in Stat- Pearls, StatPearls Publishing, Treasure Island, FL, USA, 2023, https://www.ncbi.nlm.nih.gov/books/NBK544228/. [40] S. I. Chang, B. Jin, P. Youn, C. Park, J.-D. Park, and D.-Y. Ryu, “Arsenic-induced toxicity and the protective role of ascorbic acid in mouse testis,” Toxicology and Applied Pharmacology, vol. 218, no. 2, pp. 196–203, 2007. [41] J. Mukinda and J. A. Syce, “Acute and chronic toxicity of the aqueous extract of Artemisia afra in rodents,” Journal of Ethnopharmacology, vol. 112, no. 1, pp. 138–144, 2007. [42] J. K. Limdi and G. M. Hyde, “Evaluation of abnormal liver function tests,” Postgraduate Medical Journal, vol. 79, no. 932, pp. 307–312, 2003. [43] M. Garcovich,M. A. Zocco, and A. Gasbarrini, “Clinical use of albumin in hepatology,” Blood Transfusion, vol. 7, no. 4, pp. 268–277, 2009. [44] F. B. Hu, M. J. Stampfer, E. B. Rimm, J. E. Manson, A. Ascherio, and G. A. Coldit, “A prospective study of egg consumption and risk of cardiovascular disease in men and women,” Japan Automobile Manufacturers Association, vol. 281, no. 15, pp. 1387–1394, 1999. [45] M. F. Baird, S. M. Graham, J. S. Baker, and G. F. Bickerstaf, “Creatine-kinase-and exercise-related muscle damage impli- cations for muscle performance and recovery,” Journal of nutrition and metabolism, vol. 2012, Article ID 960363, 13 pages, 2012. [46] S. JiPing, “Efect of aqueous extract of Lycium barbarum on serum CK, CK-MB activities and myocardium injury in exhausted swimming rats,” Journal of Medicinal Plants Re- search, vol. 5, no. 14, pp. 3335–3337, 2011. [47] D. W. Moss and A. R. Henderson, “Clinical enzymology,” in Tietz Textbook of Clinical Chemistry, C. A. Brutis and E. R. Ashwood, Eds., pp. 657–667, W.B. Saunders Co, Phil- adelphia, PA, USA, 1999. [48] S. P. Bessman and C. L. Carpenter, “Te creatine-creatine phosphate energy shuttle,” Annual Review of Biochemistry, vol. 54, no. 1, pp. 831–862, 1985. [49] N. Petejova, A. Martinek, J. Zadrazil, and V. Teplan, “Acute toxic kidney injury,” Renal Failure, vol. 41, no. 1, pp. 576–594, 2019. 12 Journal of Toxicology https://www.ncbi.nlm.nih.gov/books/NBK544228/